ISAL 2019 | Developing targeted therapies for AML: subgroups and trial design

Name: Developing targeted therapies for AML: subgroups and trial design
Uploaded: 2019-02-24T00:00:00.000Z
Duration: 1 min 2 s
Description: Why has it been difficult to develop targeted therapies for acute myeloid leukemia (AML), and where does current knowledge direct us for future targeted approaches? Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses this with us at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Mark Levis • 24 Feb 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia

Why has it been difficult to develop targeted therapies for acute myeloid leukemia (AML), and where does current knowledge direct us for future targeted approaches? Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses this with us at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.